Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Theo Melas-Kyriazi
AddedFeb 15, 2024
UpdatedMay 31, 2026
Theo Melas-Kyriazi

Theo Melas-Kyriazi

Board Member, Kaleido Biosciences

The Org

Theo Melas-Kyriazi's Career

Kaleido Biosciences
Kaleido Biosciences

Lexington, MA, US

Board Member· Board
Cygnal Therapeutics
Cygnal Therapeutics

Cambridge, MA, US

Board Member· Board
KSQ Therapeutics
KSQ Therapeutics

Cambridge, MA, US

Board Member· Board

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Theo Melas-Kyriazi's Career

Kaleido Biosciences
Kaleido Biosciences
Public$230.9M762015Lexington, MA, US
Board Member· Board

Leadership at Kaleido Biosciences

Alison LawtonAlison LawtonBoard Member
Geoffrey von MaltzahnGeoffrey von MaltzahnCo-Founder
Anthony QuinnAnthony QuinnBoard Member
Mike BonneyMike BonneyBoard Member
Jean MixerJean MixerBoard Member
R Grady BurnettR Grady BurnettBoard Member
Cygnal Therapeutics
Cygnal Therapeutics
Series D$65M372016Cambridge, MA, US
Board Member· Board

Leadership at Cygnal Therapeutics

Noubar AfeyanNoubar AfeyanBoard Member
Avak KahvejianAvak KahvejianCo-Founder
Jordi Mata-FinkJordi Mata-FinkCo-Founder
Michael RosenblattMichael RosenblattBoard Member

Similar to Cygnal Therapeutics

SynerGene TherapeuticsSynerGene TherapeuticsPotomac, MD, USCancer Therapeuticsest. 1998SynerGene TherapeuticsPotomac, MD, US · est. 1998

SynerGene Therapeutics: A biopharmaceutical firm innovating nanotech cancer treatments.

Series A · $10.3M5
Signet TherapeuticsSignet TherapeuticsNewton, MA, USCancer Drugsest. 2020Signet TherapeuticsNewton, MA, US · est. 2020

Signet Therapeutics, a biopharmaceutical startup, innovates targeted cancer drugs using unique disease models.

Seed · $20M30
Exalys TherapeuticsExalys TherapeuticsSan Diego, CA, USDrugs, Therapeuticsest. 2018Exalys TherapeuticsSan Diego, CA, US · est. 2018

Exalys Therapeutics develops novel anti-inflammatory drugs, targeting diseases with limited treatments.

Series A · $15M32
Cytonus TherapeuticsCytonus TherapeuticsCarlsbad, CA, USDrug Deliveryest. 2018Cytonus TherapeuticsCarlsbad, CA, US · est. 2018

Cytonus Therapeutics: Innovating precise, safe, and controlled drug delivery with our unique Cargocyte platform.

Series A · $18.9M13
KSQ Therapeutics
KSQ Therapeutics
Series C$156M852015Cambridge, MA, US
Board Member· Board

Leadership at KSQ Therapeutics

Mahesh KarandeMahesh KarandeBoard Member
David M. SabatiniDavid M. SabatiniFounder
George GolumbeskiGeorge GolumbeskiBoard Member
Frank StegmeierFrank StegmeierBoard Member
Pearl HuangPearl HuangBoard Member
Richard MoscickiRichard MoscickiBoard Member

Similar to KSQ Therapeutics

NKT TherapeuticsNKT TherapeuticsWaltham, MA, USTherapeuticsNKT TherapeuticsWaltham, MA, US

NKT Therapeutics: A US-based biotech firm dedicated to developing treatments for cancer and serious diseases.

Series A · $12M8
Nested TherapeuticsNested TherapeuticsCambridge, MA, USTherapeuticsest. 2021Nested TherapeuticsCambridge, MA, US · est. 2021

Nested Therapeutics: A biotech innovator designing impactful therapeutics through creative service.

Series A · $125M50
Celsius TherapeuticsCelsius TherapeuticsCambridge, MA, USTherapeuticsest. 2018Celsius TherapeuticsCambridge, MA, US · est. 2018

Celsius Therapeutics, a US-based biotech firm, develops drugs for cancer and autoimmune diseases.

Series B · $148M72

Theo Melas-Kyriazi's Similar Executives & Operators

Lau Eng BoonLau Eng BoonBoard Member · BukalapakJay Geoffrey WacherJay Geoffrey WacherBoard Member · BukalapakSoemantri BrodjonegoroSoemantri BrodjonegoroBoard Member · BukalapakWILL WEI CHENGWILL WEI CHENGBoard Member · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniBoard Member · Reliance RetailMason YeoMason YeoBoard Member · KakaoJaeHong ChoiJaeHong ChoiBoard Member · KakaoSean JohSean JohBoard Member · Kakao

People Similar to Theo Melas-Kyriazi

Qasim RizviQasim RizviBoard Member · KSQ TherapeuticsPaul YuPaul YuBoard Member · Keros TherapeuticsThomas B. KingThomas B. KingBoard Member · Concentric AnalgesicsIan ClarkIan ClarkBoard Member · Kyverna Therapeutics